Relapsed or Refractory Diffuse Large B-Cell Lympho | Norton Healthcare

Indication: Relapsed or Refractory Diffuse Large B-Cell Lympho

A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of
Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Sub-indication: Hematological Malignancies

Study Type: Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Sponsor: Merck & Co., Inc

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.